Analysis of Regressive Changes in the Lung Carcinoma Lymphatic Metastases Following Induction Chemotherapy
Authors:
J. Klein 1; T. Tichý 2; V. Král 1; Č. Neoral 1; T. Bohanes 1; M. Szkorupa 1; V. Kolek 3; M. Heřman 4; T. Janásková 5
Authors‘ workplace:
I. chirurgická klinika LF UP a FN Olomouc, přednosta: doc. MUDr. Č. Neoral, CSc.
1; Klinika plicních nemocí a tuberkulózy LF UP a FN Olomouc, přednosta: prof. MUDr. V. Kolek, DrSc.
2; Ústav patologie LF UP a FN Olomouc, přednosta: prof. MUDr. Z. Kolář, DrSc.
3; Radiologická klinika LF UP a FN Olomouc, přednosta: prof. MUDr. M. Heřman, Ph. D.
4; Plicní oddělení Vítkovické nemocnice, a. s., primář: MUDr. T. Janásková
5
Published in:
Rozhl. Chir., 2007, roč. 86, č. 4, s. 206-211.
Category:
Monothematic special - Original
Overview
Background:
Prognosis of higher stages of non-small cell lung cancer (NSCLC) is very poor. Only 13% of patients in stage IIIA survive 5 years after the diagnosis determination. The purpose of neoadjuvant (inductive) therapy is to eliminate haematogenous and lym-phogenous metastases and to cause a cytoreduction in the primary tumor before the resection. Especially detection of lymphogenous metastases is the main factor in the indication of the pre-operative chemotherapy, but this therapy is frequently indicated according to CT without any bioptic verification. The authors suppose such a discrepancy in radiological and histo-pathological staging to influence in a positive sense rather optimistic results of therapeutic protocols, which include the pre-operative chemotherapy
Methods:
A biopsy of the lymph nodes was performed as a part of the staging. If the metastasis was proved, the lymph node was labeled and the patient was treated by 3 cycles of the pre-operative chemotherapy. The 57 labeled lymph nodes were removed during the subsequent lung resection and lymphadenectomy. An analysis of regressive alterations in the lymphatic metastases of lung cancer after an inductive chemotherapy and comparison with the pre-operative bioptic findings have quantificated the chance of the inductive therapy to eliminate lymphatic metastases.
Results:
The clinical down-staging was stated in 21 cases (36.8%), but the viable malignant cells rested in the majority 50 (87.7%) of the taken labeled lymph nodes 57 (100 %) even after the neoadjuvant therapy. On the other hand, the satisfactory tumor regression changes was proven in 49 (86%) lymphatic metastases.
Conclusin:
The results of the study may modify an indicating judgment in the therapy of locally advanced stages of lung cancer because it has brought a new view to the results of neoadjuvant therapy.
Sources
1. Baas P. Inductive and adjuvant treatment strategies for localized non-small cell lung cancer in operable and inoperable patients. Curr. Opin. Oncol. 2002, 14, 180-4.
2. Klein J., Král V., Neoral Č., et al. Lung resection in a neoadjuvant protocol. Medic. Sci. Monit., 2000., 6, 937–941.
3. Junker, K., Langner, K., Klinke, F., et al. Grading of tumor regression in non-small cell lung cancer. Chest, 2001, 120, 1584–1591.
4. Langner, K., Thomas, M., Klinke, F., et al. Neoadjuvant therapy in non-small cell lung cancer. Prognostic impact of „mediastinal downstaging“. Der Chirurg, 2003, 74, 42–48.
5. Mandard, A. M., Dalibardm F., Mandardm J. C., at al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer, 1994; 73(11): 2680–2686.
6. Eberhardt, W. E., Albain, K. S., Pass, H., et. al. Induction treatment before surgery for non-small cell lung cancer. Lung Cancer, 2003; 42 Suppl. 1: S9-14. Review.
7. Atkins, B. Z., Amico, T. A. Controversial issues regarding the use of induction chemotherapy for lung cancer. Semin. Thorac. Cardiovasc. Surg., 2005 Fall; 17(3):191–194. Review.
8. Granetzny, A., Striehn, E., Bosse, U., et al. Remission rate of mediastinal lymph nodes after multimodal therapy of lung cancer – is it prognostic factor? Zentralbl. Chir., 2003, 128, 640–646.
9. Jaklish, M. T., Herndon, J. E., De Camp, M. M., et al. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. J. Surg. Oncol., 2006; 94(7): 599–606.
10. Junker, K., Mueller, K. M., Bosse, F., et al. Apoptose und Tumorregression bei neoadjuvant behandelten lokal fortgeschrittenen nichtkleincelligen Lungenkarcinomen. Der Pathologe, 2003, 24, 214–219.
11. Král, V., Hajdúch, M., Neoral, Č., et al. Význam a možnosti současné cytostatické léčby maligních nádorů: testování účinnosti cytostatik. Rozhl. Chir., 2000, 79, 3, 134–138.
12. De Leyn, P., Stroobants, S., De Wever, W., et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J. Clin. Oncol., 2006; 24(21): 3333–3339.
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2007 Issue 4
Most read in this issue
- Treatment of Gunshot Wounds and Prevention of Complications during the Healing Process
- Surgical Treatment of Bleeding Gastroduodenal Ulcer
- Acute Intestinal Ischaemia
- Long-term Results after Radical Resections for Pancreatic Ductal Adenocarcinoma – 10 Years Experience